Literature DB >> 34409613

55 years in the life of Clinical & Experimental Immunology.

Leonie S Taams1, Matthew Perryman2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34409613      PMCID： PMC8374229          DOI： 10.1111/cei.13652

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   5.732


× No keyword cloud information.
  16 in total

1.  Immunosenescence: the importance of considering age in health and disease.

Authors:  B Weinberger
Journal:  Clin Exp Immunol       Date:  2017-01       Impact factor: 4.330

2.  Regulation of Leishmania populations within the host. III. Mapping of the locus controlling susceptibility to visceral leishmaniasis in the mouse.

Authors:  D J Bradley; B A Taylor; J Blackwell; E P Evans; J Freeman
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

3.  Interactions of the microbiota with the mucosal immune system.

Authors:  Calum C Bain; Vuk Cerovic
Journal:  Immunology       Date:  2019-11-27       Impact factor: 7.397

4.  Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells.

Authors:  K English; J M Ryan; L Tobin; M J Murphy; F P Barry; B P Mahon
Journal:  Clin Exp Immunol       Date:  2009-02-03       Impact factor: 4.330

5.  Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines.

Authors:  L A Dieleman; M J Palmen; H Akol; E Bloemena; A S Peña; S G Meuwissen; E P Van Rees
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

6.  Regulation of Leishmania populations within the host. II. genetic control of acute susceptibility of mice to Leishmania donovani infection.

Authors:  D J Bradley
Journal:  Clin Exp Immunol       Date:  1977-10       Impact factor: 4.330

7.  Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice.

Authors:  D J Bradley; J Kirkley
Journal:  Clin Exp Immunol       Date:  1977-10       Impact factor: 4.330

8.  Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.

Authors:  H Hou; B Zhang; H Huang; Y Luo; S Wu; G Tang; W Liu; L Mao; L Mao; F Wang; Z Sun
Journal:  Clin Exp Immunol       Date:  2020-05-15       Impact factor: 4.330

Review 9.  COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.

Authors:  D Baker; C A K Roberts; G Pryce; A S Kang; M Marta; S Reyes; K Schmierer; G Giovannoni; S Amor
Journal:  Clin Exp Immunol       Date:  2020-08-01       Impact factor: 4.330

Review 10.  Vaccines for COVID-19.

Authors:  J S Tregoning; E S Brown; H M Cheeseman; K E Flight; S L Higham; N-M Lemm; B F Pierce; D C Stirling; Z Wang; K M Pollock
Journal:  Clin Exp Immunol       Date:  2020-10-18       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.